NexGel, Inc.
General Information | |
Business: | NEXGEL is a leading provider of ultra-gentle high-water-content hydrogels for healthcare and consumer applications. We have developed and manufactured electron-beam cross-linked hydrogels for over two decades. Alongside our strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation. We specialize in custom polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. We have historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products and have recently began producing our own consumer products using our gels focused on proprietary branded products and white label opportunities. Both our gels and our consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable us to produce gels that can satisfy rigid tolerance specifications with respect to a wide range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate (a measure of the passage of water vapor through a substance) and release rate) while maintaining product integrity. Additionally, we have the manufacturing ability to offer broad choices in the selection of liners onto which the gels are coated. Consequently, we and our customers are able to determine tolerances in moisture vapor transmission rate and active ingredient release rates while personalizing color and texture. (Note: NexGel slightly upsized its IPO – a unit offering – at pricing on Dec. 21, 2021, by increasing the number of units to 2.585 million, up from about 2.066 million units in the prospectus, and pricing the units at $5.50 each, down from $6.83, the assumed IPO price in its SEC filing, to raise $14.22 million. Each unit consists of one share of our common stock, par value $0.001 per share, and one warrant to purchase one share of our common stock. The stock and the warrants will trade on NASDAQ – with the stock symbol “NXGL” and the warrant symbol “NXGLW” – starting on Wednesday, Dec. 22, 2021.)
|
Industry: | Wound care gels/ transdermal gels |
Employees: | 10 |
Founded: | 2009 |
Contact Information | |
Address | 2150 Cabot Blvd West Suite B Langhorne, PA 19047 |
Phone Number | (215) 702-8550 |
Web Address | http://www.nexgel.com/ |
View Prospectus: | NexGel, Inc. |
Financial Information | |
Market Cap | $34.49mil |
Revenues | $1.12 mil (last 12 months) |
Net Income | $-3.35 mil (last 12 months) |
IPO Profile | |
Symbol | NXGL |
Exchange | NASDAQ |
Shares (millions): | 2.1 |
Price range | $6.83 - $6.83 |
Est. $ Volume | $14.1 mil |
Manager / Joint Managers | Maxim Group |
CO-Managers | - |
Expected To Trade: | 12/22/2021 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |